Nabriva Therapeutics plc, a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, today announced that it has acquired Zavante Therapeutics, a biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients, for upfront consideration of approximately 8.2 million of Nabriva Therapeutics’ ordinary shares (which includes an indemnity holdback) to Zavante Therapeutics’ former stockholders upon completion of the acquisition. In addition, Zavante Therapeutics’ former stockholders are eligible to receive up to $97.5 million upon the achievement of specified regulatory and commercial milestones, which subject to approval by Nabriva Therapeutics’ shareholders and specified limitations, may be settled in Nabriva Therapeutics’ ordinary shares.
Nabriva Therapeutics’ ordinary shares issued upon completion of the acquisition, together with shares that may be issuable upon release of an indemnity holdback, constitute approximately 19.9% of Nabriva Therapeutics’ ordinary shares outstanding as of immediately prior to completion of the acquisition.
“We believe the strategic acquisition of Zavante’s promising late-stage product candidate bolsters Nabriva’s leading position in developing new anti-infectives that address critical areas of unmet medical need, including antibiotic resistance,” said Colin Broom, M.D., former chief executive officer of Nabriva Therapeutics. “We expect that Nabriva’s expert commercial, medical affairs and supply chain infrastructure will be able to fully support CONTEPO, a novel, potential first-in-class IV treatment in the United States. We believe CONTEPO will be beneficial in the early, appropriate treatment of complicated urinary tract infections caused or suspected to be caused by multi-drug resistant bacteria. Nabriva expects to file New Drug Applications with the U.S. Food and Drug Administration for both lefamulin and CONTEPO in the fourth quarter of 2018.”
CONTEPO™ (fosfomycin for injection, previously referred to as ZTI-01 and ZOLYD), is Zavante Therapeutics’ novel, potentially first-in-class in the United States, intravenous investigational antibiotic. CONTEPO is in development to treat serious infections, including those caused by multi-drug resistant Gram-negative and Gram-positive bacteria. Outside of the United States, IV fosfomycin has been used broadly for over 45 years to treat a variety of indications, including complicated urinary tract infections and other serious bacterial infections. In recent years, IV fosfomycin has seen increasing use for treatment of serious infections caused by MDR Gram-negative bacteria. Zavante has been developing CONTEPO with the objective of establishing CONTEPO as a standard of care in the United States for hospitalized patients with serious infections caused by suspected or confirmed MDR bacteria. Zavante has completed a pivotal Phase 2/3 clinical trial with respect to CONTEPO for the treatment of cUTIs and has initiated a pediatric clinical trial. In April 2017, Zavante announced that CONTEPO met the primary endpoint of statistical non-inferiority to piperacillin/tazobactam in the ZEUS™ clinical trial in patients with cUTI, including acute pyelonephritis. CONTEPO has been granted Qualified Infectious Disease Product and Fast Track designations by the U.S. Food and Drug Administration in several indications, including cUTI. Nabriva Therapeutics expects to file a New Drug Application utilizing the FDA’s 505(b)(2) pathway in the fourth quarter of 2018.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Lefamulin is a semi-synthetic pleuromutilin discovered and developed by the Nabriva Therapeutics team. It is designed to inhibit the synthesis of bacterial protein, which is required for bacteria to grow. Lefamulin’s binding occurs with high affinity, high specificity and at molecular sites that are different than other antibiotic classes. Nabriva Therapeutics has completed two pivotal Phase 3 trials evaluating the safety and efficacy of lefamulin for the treatment of adults with community-acquired bacterial pneumonia. In both studies, lefamulin met all primary and secondary endpoints and was shown to be generally well tolerated. As a result of the favorable safety and tolerability profile observed in clinical trials to date, Nabriva Therapeutics believes lefamulin represents a potentially important new treatment option for the approximately three million adults in the United States diagnosed with CABP in the hospital setting each year.
“With this acquisition, Nabriva strengthens its antibiotics leadership position with two late-stage antibiotics with novel mechanisms of action. Nabriva shares Zavante’s deep commitment to addressing the growing global problem of antibiotic resistance by providing novel treatment options to physicians and patients that combat serious and life-threatening infections,” said Ted Schroeder, former president and chief executive officer of Zavante. “With Nabriva’s scientific, clinical and commercial leadership, we believe the CONTEPO program can thrive and deliver the most value to our existing shareholders. I want to personally thank and recognize the contributions made by the entire team at Zavante. We’re proud of the company that we collectively built and are confident that our important mission and focus will continue under the guidance of the new team and our colleagues at Nabriva.”
WilmerHale LLP acted as legal advisor to Nabriva Therapeutics, and Latham & Watkins LLP acted as legal advisor to Zavante Therapeutics, in connection with the acquisition. Bank of America Merrill Lynch acted as the financial advisor to Zavante. Wedbush PacGrow acted as an advisor to Nabriva’s Board of Directors and provided a fairness opinion.
CEO Transition
Upon closing of the acquisition, Mr. Schroeder was appointed as chief executive officer of Nabriva Therapeutics to succeed Dr. Broom, and Mr. Schroeder’s employment agreement with Nabriva Therapeutics provides that he will be appointed to Nabriva Therapeutics’ board of directors effective immediately following Nabriva Therapeutics’ 2018 Annual General Meeting of Shareholders, scheduled to be held on August 1, 2018. Dr. Broom will continue to serve on Nabriva Therapeutics’ board of directors and will work closely with Mr. Schroeder and the management team as a consultant.
“On behalf of Nabriva’s board of directors, investors and employees, we want to thank Colin for his tremendous leadership and accomplishments during his tenure as CEO,” said Dan Burgess, Nabriva’s Chairman of the Board. “Colin has led the company through many key corporate achievements, including an initial public offering, two successful Phase 3 clinical trials and the establishment of an outstanding team who are evolving Nabriva from a clinical stage to a commercial stage company with two products potentially launching in 2019.”
Prior to serving as president, CEO, founder and director of Zavante Therapeutics, Mr. Schroeder co-founded Cadence Pharmaceuticals and served as president, CEO and a member of the board of directors until the company’s acquisition by Mallinckrodt Pharmaceuticals in 2014 for $1.4 billion. He had also held several roles at Elan Pharmaceuticals including senior vice president of North American sales and marketing, and vice president and general manager of the hospital products business unit – a role he also held at Dura Pharmaceuticals before its acquisition by Elan. In this position, he was responsible for overseeing commercialization of a number of successful IV anti-infectives including Maxipime™, Azactam™ and Ablecet™. Earlier in his career, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb. He currently serves on the board of Cidara Therapeutics, Otonomy and Collegium Pharmaceutical.
“I am honored to join this outstanding team of professionals who are committed to advancing the treatment of infectious disease and look forward to planning for and successfully executing on the launch of two novel antibiotics,” said Schroeder. “We will remain focused on helping healthcare providers and patients manage the urgent public health crisis of bacterial resistance, through innovative and meaningful therapeutic solutions.”
Promotion to President and Chief Operating Officer
Upon closing of the acquisition, Dr. Steven Gelone, Nabriva’s Chief Scientific Officer and Vice President, Business & Corporate Development, has been named President and Chief Operating Officer of Nabriva, reporting to Mr. Schroeder. Along with his current responsibilities, Dr. Gelone will oversee Nabriva’s Technical Operations and Quality organizations. Dr. Gelone joined Nabriva in December 2014.
Date: July 30, 2018
Source: streetinsider
